Trial · NCT02184572
Outcomes16
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination | During Day 5 to Day 12 post-vaccination period | Analysis was performed on Total Vaccinated cohort (TVC) which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value | At Day 42 post vaccination | According to Protocol (ATP) cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | Percentage of subjects | NUMBER |
| SECONDARY | Anti-measles Virus Antibody Concentrations | At Day 42 post vaccination | ATP cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | mIU/mL | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value | At Day 42 post vaccination | ATP cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | Percentage of subjects | NUMBER |
| SECONDARY | Anti-mumps Virus Antibody Concentrations | At Day 42 post vaccination | According to Protocol (ATP) cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps, or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | EU/mL | GEOMETRIC_MEAN |
| SECONDARY | Percentage of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value | At Day 42 post vaccination | ATP cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | Percentage of subjects | NUMBER |
| SECONDARY | Anti-rubella Virus Antibody Concentrations | At Day 42 post vaccination | ATP cohort for immunogenicity: included all eligible subjects with pre and post-vaccination serology results available for at least one vaccine components of measles, mumps or rubella, who did not meet any elimination criteria up to the Visit 2 blood sample and who complied with the post dose blood sample schedule. | IU/mL | GEOMETRIC_MEAN |
| SECONDARY | Number of Subjects With Any Solicited Local Adverse Events (AEs) | During the 4-day (Days 0-3) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects With Any Solicited General AEs | During the 15-day (Days 0-14) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting Any Fever | During the 43-day (Days 0-42) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting Any Rash | During the 43-day (Days 0-42) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting MMR Specific Solicited General AEs | During the 43-day (Days 0-42) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting Any Unsolicited AEs | During the 43-day (Days 0-42) post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting AEs of Specific Interest | Day 0 through the end of the study (Day 180) | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting Any Serious Adverse Events (SAEs) | Day 0 through the end of the study (Day 180) | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Reporting Measles-like Illness | During Day 5 to Day 12 post-vaccination period | Analysis was performed on TVC which included all vaccinated subjects with administration of either Priorix or M-M-R II/M-M-R VaxPro lots documented. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02184572/outcomes